

# Dry Eye Syndrome Treatment Market: A Rapidly Expanding Healthcare Segment

PORTLAND, OR, UNITED STATES, July 7, 2025 /EINPresswire.com/ -- The global [dry eye syndrome treatment market](#) is witnessing strong growth, driven by the rising prevalence of eye disorders, increasing screen time, and a rapidly aging population. Valued at \$4.7 billion in 2022, the market is projected to more than double, reaching \$9.3 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.

Dry eye syndrome (DES), characterized by poor tear production or low tear quality, leads to symptoms like stinging, burning, redness, and a sensation of foreign particles in the eye. If left untreated, it can cause inflammation and damage to the ocular surface.

Get a Sample Copy of this Report: <https://www.alliedmarketresearch.com/request-sample/2807>

## Key Growth Drivers

**Rising Incidence of Eye Diseases:** Increasing prevalence of conditions such as dry eye disease, cataracts, and age-related macular degeneration.

**Geriatric Population:** Older adults are more susceptible to DES. Over 54 million Americans aged 65+ were reported in 2021.

**Increased Screen Time:** Prolonged use of smartphones, computers, and TVs contributes to eye strain and dryness.

**Technological Advancements:** FDA approvals for innovative drug formulations such as MIEBO and VEVYE have enhanced treatment efficacy.

## Market Trends & Developments

**Unmet Diagnosis Gap:** In the U.S., 38 million people suffer from DES, but only half are diagnosed,



**DRY EYE SYNDROME TREATMENT MARKET**  
OPPORTUNITIES AND FORECAST, 2023-2032

Dry eye syndrome treatment market is expected to reach **\$9.3 Billion** by 2032

Growing at a **CAGR of 7.1%** (2023-2032)

Report Code: A02472, [www.alliedmarketresearch.com](http://www.alliedmarketresearch.com)

Dry Eye Syndrome Treatment Market growth--

indicating major growth potential.

**Strategic Collaborations:** Companies like Bausch + Lomb, Novaliq, and AbbVie are investing in R&D, product development, and acquisitions to expand their product portfolios.

**Global Expansion:** Emerging economies such as India, China, and Brazil are witnessing rapid market expansion due to improved healthcare access and rising awareness.

## Segmental Insights

### By Drug Type

Dry Eye Syndrome Drugs held the largest market share in 2022.

Growing use of anti-inflammatory and immune-modulating eye drops is expected to maintain this trend.

### By Dosage Form

Eye Drops dominated the segment due to ease of use, availability, and quick relief properties.

Innovations in preservative-free formulations are increasing consumer preference.

### By Distribution Channel

Retail Pharmacies accounted for the highest share in 2022.

Growth in e-commerce and online consultations is fueling the rise of online providers as a significant channel.

## Regional Outlook

North America leads the market, supported by advanced healthcare infrastructure and high prevalence of dry eye-related disorders.

Asia-Pacific is poised to grow at the fastest pace due to a large aging population, growing urbanization, and increasing access to eye care.

## Recent Market Highlights

### Product Approvals:

MIEBO (May 2023) – First FDA-approved drug targeting tear evaporation.

VEVYE (June 2023) – FDA approval for cyclosporine-based treatment.

### Strategic Acquisitions:

Bausch + Lomb acquired XIIDRA (June 2023) from Novartis, expanding its dry eye treatment

offerings.

AbbVie acquired Allergan (February 2022), strengthening its portfolio of eye care products.

Major Market Players

AbbVie

Viatis

Novartis AG

Bausch & Lomb

Alcon

Johnson & Johnson

Santen Pharmaceutical

Novaliq

AFT Pharmaceuticals

Sun Pharma

These companies are investing in innovative drug development, strategic partnerships, and expanding their reach in high-growth regions to gain competitive advantage.

Conclusion

The dry eye syndrome treatment market is set to witness robust expansion over the next decade. Growing awareness, technological advancements, and increasing diagnoses are expected to unlock substantial opportunities for pharmaceutical companies, eye care providers, and investors alike.

Key Takeaways:

Market projected to grow at 7.1% CAGR through 2032.

Eye drops and dry eye drugs lead the product segments.

Retail pharmacies and online providers are emerging as major distribution channels.

North America leads in share; Asia-Pacific fastest growing region.

Strategic FDA approvals and acquisitions are shaping future growth.

Enquire Before Buying: <https://www.alliedmarketresearch.com/purchase-enquiry/2807>

David Correa

Allied Market Research

+ 1800-792-5285

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[YouTube](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/828965646>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.